AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Tech bio, the amalgamation of biology and technology, aims to tackle crucial issues like curing diseases, improving agriculture, and developing renewable energy sources. This field is at the forefront of digitizing biologists, integrating DNA synthesis and sequencing with digital data processing, and applying machine learning to decipher biological information efficiently.
Synthetic biology firms like C2I epitomize the transition from wet biology to software bio, where their focus merges biological processes with signal processing and software technologies. The shift towards digital biology, computational advances, and automation is transforming the way these companies operate, enabling high throughput processes in previously labor-intensive tasks.
The fusion of biology and technology is reshaping various sectors like materials, energy, and agriculture. The advanced capabilities of tech bio are poised to revolutionize industries by offering solutions that mirror science fiction, such as personalized cell therapies and innovative genome editing tools, driving significant advancements in cancer treatment and beyond.
C2I Genomics pioneers liquid biopsy technology for real-time cancer monitoring through simple blood samples. Their innovative approach involves whole genome sequencing of cancer biomarkers in the bloodstream, leading to early cancer detection and treatment assessment, offering a personalized and optimized patient care strategy.
Establishing a diverse and supportive team comprised of experts from various backgrounds is crucial for navigating the challenges of startup ventures. C2I's strategic recruitment approach emphasizes the importance of talent diversification in areas like biology, software engineering, and business development to foster innovation and sustain growth.
The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated.
C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology.
Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future.
Asaf and Omri's conversation begins at 11:15
Visit C2i to learn more - https://c2i-genomics.com/
(0:00) Introduction and Discussion on Synthetic Biology and Tech Bio (1:24) Introduction to Omri Amirav-Drory and NFX Bio (3:03) Impact of Tech Bio on Various Industries and Future Developments (6:28) Introduction to Pete and Liquid Biopsy for Cancer Monitoring (11:18) NFX Bio Investment Thesis and Conversation with Asaf Zviran, CEO and Founder of C2I (25:23) Asaf Zviran on Managing a Diverse Team and Overcoming Challenges (29:43) Hiring, Recruiting, and Fundraising Strategies in a Virtual World (31:20) Balancing Science and Business in a Startup and Transition from Academia to Industry (38:07) End of Part 1 and Transition to Part 2: Series B Funding and Scaling Up (41:46) Overcoming Challenges in Bio Startups and Future of Cancer Treatment (44:51) Advices for Startup Founders and Quick-fire Round (48:25) Closing Remarks and End of EpisodeListen to all your favourite podcasts with AI-powered features
Listen to the best highlights from the podcasts you love and dive into the full episode
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
Listen to all your favourite podcasts with AI-powered features
Listen to the best highlights from the podcasts you love and dive into the full episode